The applicant appears in FDA device records as GE Medical Systems Ultrasound and Primary Care Diagnostics, LLC, with a Waukesha, Wisconsin address on the October 2, 2026 clearance letter for K261933. The cleared trade names are the Voluson Expert 18, Voluson Expert 20 and Voluson Expert 22, classified as an ultrasonic pulsed Doppler imaging system under 21 CFR 892.1550 in Class II, with product codes IYN, IYO and ITX. The same three model names appear in earlier FDA correspondence tied to the same regulation and product-code set, which places this clearance within a documented line of Voluson Expert submissions rather than an isolated filing. [1][2][9]
The K261933 clearance and its scope
FDA records show K261933 received on June 9, 2026 and decided on October 2, 2026 with decision code SESE, described as substantially equivalent, under a traditional clearance type with a summary statement. The reviewing advisory committee is listed as Radiology, and the openFDA device record names the device as a pulsed Doppler ultrasonic imaging system in Class II under regulation number 892.1550. The submission lists product code IYN, and the clearance letter adds IYO and ITX. [1][2]
The applicant's stated conclusion in the K261933 documentation rests on equipment design similarities, conformance to recognized performance standards and performance testing, with the Voluson Expert Series 18/20/22 described as performing in a substantially equivalent manner to the predicate device. That conclusion is the applicant's position as recorded in the filing, not an independent clinical finding. [2]
Documented product line and stated features
The manufacturer's published Voluson Expert 22 page describes next-generation imaging built on what it calls the Lyric Architecture, addressing 2D as well as 3D/4D imaging, and states the system is designed for early detection. The same page references an endocavitary (transvaginal) transducer for early gestation and gynecological imaging, a component described in the K261933 documentation. These are manufacturer statements about the product, not verified test results. [5][2]
GE HealthCare's Voluson product page frames the family around women's health imaging. The page carries a June 2026 document reference, which is a publication marker rather than a regulatory date. [7]
Earlier filings for the same model names
FDA correspondence dated June 6, 2022 for K220358 names the Voluson Expert 22, Voluson Expert 20 and Voluson Expert 18 under the same regulation, Class II, and product codes IYN, IYO and ITX. That document states the subject devices did not require clinical studies to support substantial equivalence and records the applicant's conclusion of substantial equivalence to the predicate devices. [9]
A December 20, 2024 letter for K242168 and a November 24, 2025 letter for K252328 repeat the same three trade names, regulation and class, and add product code QIH to the earlier IYN, IYO and ITX set. The 2024 letter records the applicant's view that the series is as safe, as effective and substantially equivalent to the primary predicate device. The 2025 letter references minor software improvements and bug fixes alongside an AI testing summary for a first-trimester feature. [8][6]
What the record does and does not establish
The linked collection for this applicant, as of November 20, 2026, contains one 510(k) record, K261933, and that single record carries a SESE decision; the sample of one record shows the same decision. These counts describe the linked filings at that date and are not measures of total portfolio, sales or safety performance. No recall records appear in the linked sample. [1]
The filings identify a regulatory contact and a Waukesha, Wisconsin address for correspondence; that address is a filing address and does not establish a corporate headquarters. Ownership, parent-company relationships, customers, commercial availability and independent performance data are not established by these documents. The Voluson brand appears in manufacturer materials, while the FDA applicant of record is the limited liability company named above. [1][2][5]
